References
- http://www.als.net/forum/yaf_postst52600_Is-Propofol-the-Cure-for-ALS.aspx, cited 6/21/13.
- http://www.alsuntangled.com/open.php, cited 6/24/13.
- http://en.wikipedia.org/wiki/Propofol, cited 6/24/13.
- http://news.stlpublicradio.org/post/missouri-opts-untested-drug-executions, cited 6/24/13.
- http://www.nytimes.com/2009/08/07/us/07propofol.html?_, cited 6/24/13
- Kranioti EF, Mavroforou A, Mylonakis P, Michalodimitrakis M. Lethal self administration of propofol (diprivan): a case report and review of the literature. Forensic Sci Int. 2007;167:56–8.
- http://www.washingtonpost.com/wp-dyn/content/article/2009/ 08/24/AR2009082402193.html?hpid = moreheadlines, cited 6/24/13.
- Kotani Y, Shimazawa M, Yoshimura S, Iwama T, Hara H. The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties. CNS Neuroscience & Therapeutics. 2008;14:95–106.
- Haeseler G, Karst M, Foadi N, Gudehus S, Roeder A, Hecker H, et al. High-affinity blockage of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues. Br J Pharmacol. 2008;155:266–75.
- Krasowski M, Jenkins A, Flood A, Kung A, Hopfinger A, Harrison N. General anesthetic potencies of a series of propofol analogs correlate with potency for potentiation of GABA current and the GABA-A receptor but not with lipid solubility. JPET. 2001;297:338–51.
- Martin L, Chang Q. Inhibitory synaptic regulation of motor neurons: a new target of disease mechanisms in amyotrophic lateral sclerosis. Mol Neurobiol. 2012; 45:30–42.
- Kakinohana M, Motonaga E, Saitoh T, Taira Y, Okuda Y. Propofol suppressed electromyographic fibrillation potentials on a patient with amyotrophic lateral sclerosis. J Anesth. 1999;13:122–4.
- Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?. CNS Neurosci Ther. 2011;17:4–31.
- http://blogs.als.net/post/2013/02/05/Mexiletine-channeling-ALS.aspx, cited 6/24/13.
- Fowler CJ. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends Parmacol Sci. 2004;25:59–61.
- ALSUntangled Group. ALSUntangled 16: Cannabis. Amyotroph Lateral Scler. 2012;13:400–4.
- Andersen JK. Oxidative stress in neurodegeneration: cause or consequence?. Nature Medicine. 2004;10 (Suppl): S18−25.
- Mosley RL, Gendelman HE. Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Exp Neurol. 2010; 222:1–5.
- Papadimitriou D, LaVerche V, Jacquier A, Ikiz B, Przedborski S, Re DB. Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dise. 2010;37: 493–502.
- Personal communications between Richard Bedlack, Lorne Zinman, Kristen Cox, John Fang, Mark Bromberg, Terry Heiman-Patterson.
- https://nctu.partners.org/ProACT, cited 6/28/13.
- Glass J, Boulis N, Johe K, Rutkove S, Federici T, Polak M, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase 1 trial in 12 patients. Stem Cells. 2012;30:1144–51.
- Tobias J, Leder M. Procedural sedation: a review of sedative agents, monitoring and management of complications. Saudi J Anaesth. 2011;5:395–410.
- Roberts R, Barletta J, Fong J, Schumaker G, Kuper P, Papadopoulos S, et al. Incidence of propofol-related infusion syndrome in critically ill adults: a prospective multicenter study. Crit Care. 2009;13:R169.
- Perel A. Non-anaesthesiologists should not be allowed to administer propofol for procedural sedation: a consensus statement of 21 European national societies of anaesthesia. Eur J Anaesthesiol. 2011;28:580–4.
- Cox C, Reed S, Govert J, Rodgers J, Campbell-Bright S, Kress J, Carson S. An economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med. 2008;36:706–14.
- Miyoshi K, Ohyagi Y, Amano T, Inoue I, Miyoshi S, Tsuii S, et al. A patient with motor neuron syndrome clinically similar to amyotrophic lateral sclerosis, presenting a spontaneous recovery. Rinsho Sinkeigaku. 2000;40:1090–5.
- Tsai CP, Ho HH, Yen DJ, Wang V, Lin KP, Liao KK, Wu Z. Reversible motor neuron disease. Eur Neurol. 1993; 33:387–9.
- Tucker T, Layzer R, Miller R, Chad D. Subacute, reversible motor neuron disease. Neurology. 1991;41:1541–4.
- Tucker T. Subacute, reversible motor neuron disease. Taehan Singyongkwa Hakhoe chi. 1991;41:1541.